Evaluation of GERDOFF Efficacy in Combination With Proton Pump Inhibitor

Evaluation of the Effects of GERDOFF in Combination With a 6-week Therapy Based on Proton Pump Inhibitors Versus Proton Pump Inhibitors Alone on GERD-high Symptoms in Patients With Primary Diagnosis of Gastroesophageal Reflux Disease.

The aim of the present study was to evaluate the effect of a 6-weeks treatment of a CE-marked combination oral formulation of hyaluronic acid with chondroitin sulphate and aluminium hydroxide (GERDOFF®), in addition to proton pump inhibitors (PPI) at the standard dose, versus PPI only, in patients with first diagnosed clinical presentation of extra-esophageal GERD symptoms.

The investigators verified the reduction of symptoms frequency, using a Likert questionnaire, and severity, using the Reflux Symptom Index (RSI) questionnaire, to evaluate the proportion of Responders and Non-Responder patients in these two groups after 6 weeks of treatment, compared to baseline. Moreover investigators evaluated the persistence of effects of GERDOFF® + PPI treatment on extraesophageal symptoms, after a 12-weeks follow up, only in responder patients.

Study Overview

• Status: Completed
• Conditions: Gastro-oesophageal Reflux Disease
• Intervention / Treatment: Device: GERDOFF® + Omeprazole; Drug: Omeprazole

Detailed Description

Cough, hoarseness, prolonged voice lowering, and vocal timbre modification, without any documentable cause, are considered as minor disorders for which patients do not receive adequate attention. These disorders may represent extra-esophageal manifestations of gastro-oesophagea reflux. Accurate diagnosis and gastro-oesophageal reflux therapy have been proved as useful to improve patients' quality of life.

The aim of the present study was to evaluate, in first diagnosed patients presenting with upper symptoms associated with GERD, the effect of a 6-week treatment with a combination based on CS, HA and aluminium hydroxide (Gerdoff®), co-administered with a treatment with PPIs, compared to treatment with PPIs as monotherapy, i.e. to verify, in patients treated with the combination of the two products, the reduction in symptoms frequency by means of a Likert questionnaire and the severity of upper symptoms by means of the Reflux Symptom Index (RSI) questionnaire, and to collect safety data. After 6 weeks of treatment, patients included in the two groups were then classified as responders or non-responders. Responder patients were defined as those patients that, at the 6th week of treatment, reached a RSI score decreased for at least 50% compared to baseline and an absolute value < 13.

Furthermore, the maintenance of the effect of treatment on the extra-oesophageal symptoms was evaluated after a period of follow-up lasting 12 weeks, which could be entered only by responder patients randomised in the Gerdoff®-PPI arm. Patients included in the follow-up period were randomised to receive Gerdoff® or no treatment (control group). Safety data were also evaluated in the group of patients that continued in the follow-up period.

• Study Type: Interventional
• Enrollment (Actual): 72
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Italy
  • MI
    • Rozzano, MI, Italy, 20089
      • Dr Alessandro Repici

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 16 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Male or female subjects aged ≥ 18 years;
2. First diagnosis of GERD with upper symptoms, made on a clinical basis and confirmed by an ENT and/or confirmed by a Gastroenterologist using a RSI questionnaire;
3. Presence of extra-oesophageal symptoms associated with GERD;
4. RSI score ≥ 20;
5. Patients not pre-treated with PPIs, even for problems different from GERD, and/or with medical devices and/or similar products (e.g. antacid alginates etc..) in the last 4 weeks;
6. Cooperative patients, able to understand and adhere to the study procedures;
7. Patient able to freely give their written informed consent to study participation;
8. Patients that freely gave the consent to management of personal data related to the study.

Exclusion Criteria:

1. Known infective oesophagitis or oesophagitis due to acid or alkaline substances;
2. Acute or chronic rhinosinusitis;
3. Chronic bronchitis;
4. Known Zollinger-Ellison syndrome, hiatal hernia greater than 3 cm and Barrett oesophagus;
5. Ongoing neoplasias;
6. Uncontrolled diabetes;
7. Patients with impaired liver function;
8. Patients with rare hereditary problems of galactose intolerance;
9. Patients that, based on Investigator's opinion, could not take part in the study due to other diseases or concomitant therapies, such as the intake of atazanavir, nelfinavir, clopidogrel, posaconazole and erlotinib (as recommended in the Summary of Product Characteristics of Gerdoff®);
10. Patients with deficiency of Lapp lactase;
11. Patients with syndrome of glu-gal malabsorption;
12. Patients with hypersensitivity to omeprazole, substitute benzymidazolic or any of the excipients;
13. Patients already in treatment with PPIs or similar products;
14. Chronic use of drugs that interfere with the salivary secretion (e.g. anti-histamines or inhaled steroids);
15. Abuse of drug or alcohol;
16. Inability of the subject to adequately express his/her disturbances;
17. Patients with planned or ascertained pregnancy or that did not adopt an accepted contraceptive method;
18. Lactating patients.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: GERDOFF® + omeprazole; GERDOFF® (tablets) was orally administered 3 times per day after meals; omeprazole was orally administered once a day before breakfast (2 capsules). The treatment lasted 6 weeks (+/- 2 days). Omeprazole was orally administered once a day before breakfast (2 capsules). The treatment lasted 6 weeks (+/- 2 days).	Device: GERDOFF® + Omeprazole; GERDOFF® Hyaluronic acid + chondroitin sulphate + hydroxide aluminium Melt-in-mouth tablet 1100 mg + Omeprazole was orally administered once a day before breakfast (2 capsules). The treatment lasted 6 weeks (+/- 2 days).; Other Names: GERDOFF®
Active Comparator: Omeprazole; Omeprazole was orally administered once a day before breakfast (2 capsules). The treatment lasted 6 weeks (+/- 2 days).	Drug: Omeprazole; Omeprazole, 2 capsules 20 mg, once a day before breakfast; Other Names: Omeprazen

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change From Baseline to Visit V4 of the Total Score of RSI Questionnaire	After 6 weeks of treatment, the changes from baseline in the score of Reflux Symptom Index questionnaire were evaluated to verify the effects of treatments on high symptoms. The RSI questionnaire examines 9 items that are scored from 0 to 5, with a higher score that indicates a higher severity of the symptom (range of total score: 0-45).	In the first visit (baseline) and in the visit 4 (after 6 weeks of treatment)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Total Score of Reflux Symptom Index Questionnaire in All Time-points Assessed	Total score of the Reflux Symptom Index questionnaire assessed in all time-points. The RSI questionnaire examines 9 items, that are scored from 0 to 5, with a higher score that indicates a higher severity of the symptom (range of total score: 0-45).	In baseline Visit, Visit 2 (after 1 week), Visit 3 (after 3 weeks) and Visit 4 (after 6 weeks of treatment)
Score of Hoarseness or Vocal Problem of the RSI Questionnaire Measured at the Baseline and in the Visit 4	The Reflux Symptom Index questionnaire examines 9 items, including hoarseness or vocal problem that is score from 0 to 5, with a higher score that indicates a higher severity of the symptom.	At baseline and in the visit 4, after 6 weeks of treatment
Score of Throat of the RSI Questionnarie Measured at the Baseline and in the Visit 4 of the RSI Questionnaire Score of Throat Clearance	The Reflux Symptom Index questionnaire examines 9 items, including throat that is score from 0 to 5, with a higher score that indicates a higher severity of the symptom.	At baseline and in the visit 4, after 6 weeks of treatment
Score of Excess of Mucus in the Throat or Retrosternal Fall of Secretions of the RSI Questionnaire Measured at Baseline and in the Visit 4	The Reflux Symptom Index questionnaire examines 9 items, including excess of mucus in the throat or retrosternal fall of secretions that is score from 0 to 5, with a higher score that indicates a higher severity of the symptom.	At baseline and in the visit 4, after 6 weeks of treatment
Score of Difficulty in Swallowing Food, Fluids or Pills of the RSI Questionnaire Measured at Baseline and in the Visit 4	The Reflux Symptom Index questionnaire examines 9 items, including difficulty in swallowing food, fluids or pills that is score from 0 to 5, with a higher score that indicates a higher severity of the symptom.	At baseline and in the visit 4, after 6 weeks of treatment
Score of Cough of the RSI Questionnaire Measured at Baseline and in the Visit 4 After the Meal or After Lying	The Reflux Symptom Index questionnaire examines 9 items, including cough that is score from 0 to 5, with a higher score that indicates a higher severity of the symptom.	At baseline and in the visit 4, after 6 weeks of treatment
Score of Difficulty in Breathing or Episodes of Choking of the RSI Questionnaire Measured at Baseline and in the Visit 4	The Reflux Symptom Index questionnaire examines 9 items, including difficulty in breathing or episodes of choking that is score from 0 to 5, with a higher score that indicates a higher severity of the symptom.	At baseline and in the visit 4, after 6 weeks of treatment
Score of Problematic or Troublesome Cough of the RSI Questionnaire Measured at Baseline and in the Visit 4	The Reflux Symptom Index questionnaire examines 9 items, including problematic or troublesome cough that is score from 0 to 5, with a higher score that indicates a higher severity of the symptom.	At baseline and in the visit 4, after 6 weeks of treatment
Score of Sensation of Something Blocked or Mass in the Throat of the RSI Questionnaire Measured at Baseline and in the Visit 4	The Reflux Symptom Index questionnaire examines 9 items, including sensation of something blocked or mass in the throat that is score from 0 to 5, with a higher score that indicates a higher severity of the symptom.	At baseline and in the visit 4, after 6 weeks of treatment
Score of Stomach Burning, Thoracic Pain, Poor Digestion of Gastric Acid That Moves Upright of the RSI Questionnaire Measured at Baseline and in the Visit 4	The Reflux Symptom Index questionnaire examines 9 items, including stomach burning, thoracic pain, poor digestion of gastric acid that moves upright that is score from 0 to 5, with a higher score that indicates a higher severity of the symptom.	At baseline and in the visit 4, after 6 weeks of treatment
Number of Responders V4	A responder was defined as a patient who at the 6th week of treatment showed a reduction of at least 50% vs. the baseline and an absolute value < 13 on the RSI questionnaire.	At visit 4 after 6 weeks of treatment
Number of Responders V6	Responder patients of Group Gerdoff® + omeprazole were randomly assigned to receive a treatment with Gerdoff®-one tablet three times daily- All patients received a packaging of omeprazole, to be taken only if necessary, at constant dose and according to the indications of the Investigator. The scheduled duration of the follow-up period was 12 weeks. A responder was defined as a patient who at the 6th week of treatment showed a reduction of at least 50% vs. the baseline and an absolute value < 13 on the RSI questionnaire.	In the Visit 6 at the end of follow-up
Score of Upper Symptoms Using the Likert Scale at Baseline and in the Visit V4	The Likert scale examines 9 symptoms, to be scored from 0 to 4, with a higher score indication a higher frequency of the symptom (i.e. 0=never, 1=occasionally, 2=sometimes, 3= often, 4=Always); The Likert scale scores of single items are as following: Hoarseness or vocal problem 0 1 2 3 4; Throat clearance 0 1 2 3 4; Excess of mucus in the throat or retrosternal fall of secretions 0 1 2 3 4; Difficulty in swallowing food, fluids or pills 0 1 2 3 4; Cough after the meal or after lying 0 1 2 3 4; Difficulty in breathing or episodes of choking 0 1 2 3 4; Problematic or troublesome cough 0 1 2 3 4; Sensation of something blocked or mass in the throat 0 1 2 3 4; Stomach burning, thoracic pain, poor digestion of gastric acid that moves upright 0 1 2 3 4. Subscales are summarized to compute a total score (total score ranges from 0-36). The mean values of Likert scale total score are reported.	At baseline and in the visit 4
Presence of Upper Symptoms at Visit 4, Using the RSI Questionnaire	The Reflux Symptom Index questionnaire examines 9 items, to be scored from 0 to 5, with a higher score indication a higher severity of the symptom (range of total score: 0-45).	At visit 4 after weeks of treatment
Use of Rescue Medication (Omeprazole) During the Treatment	In the first 6 weeks of treatment, the intake in each treatment group of the rescue medication, allowed or not allowed, was calculated as the frequency of intake of the specific drug and the comparison between groups was performed using the Fisher's exact test.	From baseline to visit 4
Use of Rescue Medication (Omeprazole) During the Follow-up	During the follow-up, the intake in each treatment group of the rescue medication, allowed or not allowed, was calculated as the frequency of intake of the specific drug.	In the Visit 6 after 12 weeks from baseline
Use of Rescue Medication (Other Than Omeprazole) During Treatment	During treatment, the intake in each treatment group of the rescue medication, allowed or not allowed, was calculated as the frequency of intake of the specific drug.	From baseline to visit 4
Patients'Satisfaction	This evaluation was expressed with a semi-quantitative ordinal scale: 0 = low, 1 = discrete, 2 = good, 3 = excellent).	At visit 4 after weeks of treatment

Collaborators and Investigators

• Sponsor: SOFAR S.p.A.
• Investigators: Principal Investigator: Alessandro Repici, MD, Istituto Clinico Humanitas

Study record dates

Study Major Dates

• Study Start (Actual): May 5, 2017
• Primary Completion (Actual): September 20, 2018
• Study Completion (Actual): December 11, 2018

Study Registration Dates

• First Submitted: December 11, 2018
• First Submitted That Met QC Criteria: January 3, 2019
• First Posted (Actual): January 4, 2019

Study Record Updates

• Last Update Posted (Actual): March 31, 2020
• Last Update Submitted That Met QC Criteria: March 18, 2020
• Last Verified: March 1, 2020

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Digestive System Diseases; Gastrointestinal Diseases; Esophageal Motility Disorders; Deglutition Disorders; Esophageal Diseases; Gastroesophageal Reflux; Molecular Mechanisms of Pharmacological Action; Enzyme Inhibitors; Gastrointestinal Agents; Anti-Ulcer Agents; Proton Pump Inhibitors; Omeprazole
• Other Study ID Numbers: PSC-DS GERD AP 16

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No